Home » Healthcare » Benign Prostatic Hyperplasia Treatment Market

Benign Prostatic Hyperplasia Treatment Market

Benign Prostatic Hyperplasia Treatment Market By Drugs (Alpha Blockers, 5-alpha Reductase Inhibitors, Combination Drugs); By Surgery (Transurethral Resection of the Prostate, UroLift System, Rezūm Water Vapor Therapy, Open Prostatectomy, Laser Surgery); By End-user (Hospitals, Clinics, Ambulatory Surgical Centers, Homecare) – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Summary
Table Of Content

REPORT ATTRIBUTE	DETAILS
Historical Period	2020-2023
Base Year	2024
Forecast Period	2025-2032
Benign Prostatic Hyperplasia Treatment Market Size 2024	USD 2.12 Million
Benign Prostatic Hyperplasia Treatment Market, CAGR	9.2%
Benign Prostatic Hyperplasia Treatment Market Size 2032	USD 4.29 Million

Market Overview:

Benign Prostatic Hyperplasia Treatment Market size was valued at USD 2.12 billion in 2024 and is anticipated to reach USD 4.29 billion by 2032, at a CAGR of 9.2% during the forecast period (2024-2032).

Key factors propelling the BPH treatment market include the expanding geriatric male population and the growing adoption of minimally invasive surgical procedures. As men age, the likelihood of developing BPH increases, with studies indicating that approximately 50% of men over 50 and up to 90% of men over 80 are affected. Additionally, the shift towards minimally invasive treatments, such as laser therapies and UroLift systems, is enhancing patient outcomes and reducing recovery times, thereby driving market demand. Furthermore, the increasing awareness and preference for outpatient procedures are also contributing to the market’s expansion. Technological advancements, such as the development of more precise diagnostic tools, are expected to further boost the demand for effective BPH treatments, providing better patient outcomes with fewer side effects.

Regionally, North America dominates the BPH treatment market, accounting for a significant share due to advanced healthcare infrastructure, high healthcare expenditure, and a substantial elderly population. The United States, in particular, leads in market size and growth, driven by its robust healthcare system and increasing number of men seeking treatment for BPH. Europe follows, with countries like Germany and the United Kingdom exhibiting robust market activity, supported by a well-established healthcare network and increasing government support for elderly healthcare. The Asia-Pacific region is anticipated to witness the fastest growth, fueled by a rapidly aging population, increasing healthcare investments, and rising awareness about BPH. Additionally, the growing adoption of advanced medical technologies in countries such as Japan, China, and India is expected to accelerate market penetration in the region, creating significant growth opportunities for BPH treatment providers.

Access crucial information at unmatched prices!

Request your sample report today & start making informed decisions powered by Credence Research!

Download Sample

Market Insights:

The global Benign Prostatic Hyperplasia (BPH) treatment market is expected to grow from USD 2.12 billion in 2024 to USD 4.29 billion by 2032, at a CAGR of 9.2%, driven by increasing demand for effective treatments due to the aging male population.
Key market drivers include the rising prevalence of BPH, with studies indicating that 50% of men over 50 and up to 90% of men over 80 are affected, creating a growing patient base.
Advancements in minimally invasive procedures, such as laser therapies and UroLift systems, are fueling market growth by offering quicker recovery times, fewer complications, and reducing the need for hospital stays.
Technological innovations in diagnostic tools and treatment devices are enhancing the effectiveness of BPH treatments, allowing for more personalized approaches and improved patient outcomes.
Increased awareness about BPH and the availability of treatment options is boosting demand, as public health campaigns and physician outreach programs encourage early diagnosis and intervention.
High treatment costs remain a major restraint, particularly for advanced treatments like laser therapies and UroLift systems, which are often inaccessible in regions with limited healthcare budgets.
Regional growth trends show North America holding a significant market share due to advanced healthcare infrastructure, while the Asia-Pacific region is expected to grow the fastest, fueled by an aging population and rising healthcare investments.

Market Drivers:

Growing Aging Male Population

One of the most significant drivers of the Benign Prostatic Hyperplasia (BPH) treatment market is the increasing aging population, particularly men over the age of 50. As men age, the likelihood of developing BPH rises, with an estimated 50% of men over the age of 50 and 90% of men over 80 experiencing symptoms of the condition. The growing number of elderly individuals globally is thus directly contributing to the rise in BPH diagnoses, driving demand for effective treatment options. The population shift towards an older demographic, especially in developed nations, is expected to increase the prevalence of BPH, subsequently boosting the need for both pharmaceutical and surgical treatments. This demographic trend is anticipated to be a primary market driver for BPH treatment solutions in the coming years.

Advancements in Minimally Invasive Procedures

The shift towards minimally invasive treatment options is another key driver propelling the BPH treatment market. Traditionally, BPH was treated with invasive surgeries such as prostatectomy. However, technological advancements have introduced a variety of minimally invasive procedures, including laser therapy, transurethral microwave therapy (TUMT), and UroLift systems. These treatments have gained widespread adoption due to their ability to provide effective relief with shorter recovery times, fewer complications, and reduced hospital stays. The preference for outpatient procedures is increasing, as patients seek treatments that allow them to return to their daily lives quickly. The growing popularity of these less invasive alternatives is driving the demand for modern BPH treatment options, thereby fueling the overall market growth.

Technological Innovations in Treatment Devices

Technological advancements in the development of treatment devices also play a pivotal role in the expansion of the BPH treatment market. The introduction of more precise diagnostic tools, such as advanced imaging techniques and urodynamic testing, has enabled better identification and monitoring of BPH. This, in turn, leads to more personalized treatment plans, improving the overall effectiveness of interventions. Furthermore, innovations in treatment technologies, such as high-powered lasers and newer drug delivery methods, have contributed to enhanced therapeutic outcomes for patients. For example, developments in holmium laser enucleation of the prostate (HoLEP) have allowed surgeons to perform effective outpatient surgeries. These technological improvements have enhanced the safety, efficiency, and success rates of various BPH treatments, increasing their adoption among both healthcare providers and patients. As technology continues to advance, the market for BPH treatment devices is expected to expand further, offering more effective and minimally invasive solutions.

Rising Awareness and Healthcare Access

An increase in awareness about BPH, coupled with improvements in healthcare access, is also significantly contributing to market growth. As more men become informed about BPH symptoms and the importance of early diagnosis, the demand for treatment is increasing. Public health campaigns and physician outreach programs have raised awareness about the condition, encouraging more individuals to seek medical advice and treatment options. Additionally, the expansion of healthcare infrastructure, particularly in developing regions, is making BPH treatment more accessible to a broader population. In North America, for example, the presence of specialized urology centers and advanced healthcare systems facilitates better access to both pharmaceutical and surgical treatments. With advancements in healthcare delivery and a growing number of specialized urology centers, patients have better access to treatment, thus driving the demand for effective BPH solutions. As healthcare systems continue to improve, the availability of both medical and surgical treatment options will support the ongoing growth of the BPH treatment market.

Market Trends:

Increased Adoption of Laser-Based Therapies

One of the prominent trends shaping the Benign Prostatic Hyperplasia (BPH) treatment market is the rising adoption of laser-based therapies. Procedures such as Holmium Laser Enucleation of the Prostate (HoLEP) and Photoselective Vaporization of the Prostate (PVP) are becoming increasingly popular due to their high efficacy and low complication rates. For instance, bibliometric studies have shown that Ho:YAG laser articles were cited the most between 2007 and 2018, highlighting its significance in clinical practice. These treatments are highly effective in reducing the size of the prostate, improving urinary flow, and minimizing patient recovery time compared to traditional surgical methods. The trend towards laser therapies is further driven by technological advancements, offering precision and better control during the procedure, which enhances patient outcomes. As more healthcare providers incorporate laser treatments into their practice, this trend is expected to significantly drive the growth of the BPH treatment market.

Focus on Minimally Invasive and Outpatient Procedures

The growing preference for minimally invasive procedures and outpatient treatments is another significant trend in the BPH treatment market. For example, the UroLift system has demonstrated durable, rapid symptom relief with a low retreatment rate of approximately 13.6% over five years, and its real-world effectiveness has been validated through over 145 peer-reviewed publications. These treatments do not require general anesthesia and can often be performed on an outpatient basis, reducing healthcare costs and improving convenience for patients. This trend is expected to continue as more patients opt for treatments that minimize hospital stays and offer quicker recovery times. Additionally, as the healthcare industry increasingly focuses on reducing patient costs and improving efficiency, minimally invasive treatments are likely to become the standard approach for managing BPH.

Personalized and Targeted Treatment Approaches

As the understanding of BPH continues to evolve, there is a growing trend toward personalized and targeted treatment approaches. Advances in urological diagnostics, such as genetic testing and molecular profiling, allow for better identification of BPH severity and the most appropriate treatment options for individual patients. Personalized treatments ensure that patients receive care tailored to their specific needs, improving treatment outcomes and reducing unnecessary side effects. This trend is expected to become more prevalent as precision medicine continues to make strides in various therapeutic fields, including urology. By focusing on individualized care, healthcare providers can deliver more effective treatments, enhancing both patient satisfaction and the overall success of BPH therapies.

Expansion of BPH Treatments in Emerging Markets

Another notable trend in the BPH treatment market is the expansion of treatment options into emerging markets, particularly in regions such as Asia-Pacific and Latin America. As these regions experience rapid urbanization, improvements in healthcare infrastructure, and an increase in the geriatric population, the demand for BPH treatments is growing. Many developing nations are witnessing a surge in the prevalence of BPH, which is driving the adoption of both pharmaceutical and surgical treatments. Additionally, greater awareness of BPH and its associated health risks is encouraging more individuals in these regions to seek medical care. As the market for BPH treatments in emerging economies continues to expand, it offers significant growth opportunities for manufacturers and healthcare providers, fueling the global growth of the BPH treatment market.

Market Challenges Analysis:

High Treatment Costs

One of the significant restraints affecting the growth of the Benign Prostatic Hyperplasia (BPH) treatment market is the high cost associated with advanced treatment options. Minimally invasive procedures such as laser therapies and UroLift systems, while effective, often come with a high price tag compared to traditional treatments. This can make such procedures inaccessible to a large portion of the patient population, especially in developing regions with limited healthcare budgets. High treatment costs may also place a financial burden on healthcare systems, further limiting the adoption of these advanced therapies. As a result, many patients continue to rely on less expensive pharmaceutical treatments, which may not provide long-term relief, thus impacting the overall growth of the market.

Lack of Awareness in Emerging Markets

A key challenge for the BPH treatment market is the lack of awareness surrounding the condition, particularly in emerging markets. For example, studies indicate that a large proportion of men in low-income regions have not undergone prostate screening due to limited awareness and financial constraints, despite a high willingness to get screened if informed. This lack of awareness often leads to delayed diagnosis and underutilization of advanced treatments. Additionally, in some regions, cultural stigmas associated with urological health problems may prevent patients from seeking medical advice, further hindering market growth. Efforts to educate the population about BPH and its treatments are essential to address this challenge and drive demand for more effective solutions in these regions.

Side Effects and Complications of Treatment

Another challenge that limits the widespread adoption of BPH treatments is the potential for side effects and complications associated with certain procedures. While minimally invasive treatments have lower complication rates than traditional surgeries, they are not without risks. Patients may experience adverse effects such as urinary incontinence, erectile dysfunction, or infection following surgery or laser therapy. These side effects can deter some patients from opting for these procedures, particularly those who fear post-treatment complications. As the market grows, manufacturers and healthcare providers must continue to focus on improving treatment safety profiles to mitigate these risks and enhance patient confidence in available therapies.

Market Opportunities:

The growing global geriatric population presents a significant opportunity for the Benign Prostatic Hyperplasia (BPH) treatment market. As the population of men over 50 continues to rise, the demand for BPH treatments is expected to increase substantially. With an aging demographic, more individuals will seek medical intervention to manage BPH symptoms, driving the need for both pharmaceutical and surgical treatments. The increasing recognition of the condition’s impact on quality of life is also encouraging more patients to seek timely treatment, further expanding the market. This creates opportunities for both established and emerging companies to develop innovative treatment solutions that cater to this growing patient base.

Another key opportunity lies in the advancement of minimally invasive and outpatient treatment options, such as the UroLift system and laser therapies. These procedures offer significant benefits, including shorter recovery times, reduced complications, and fewer hospital stays, making them more appealing to patients. As awareness of these treatment options continues to grow, the market for minimally invasive BPH therapies is expected to expand. Additionally, the increasing shift towards outpatient care and same-day procedures presents a unique opportunity for healthcare providers to enhance patient satisfaction while reducing healthcare costs. Companies that innovate in this space and expand their offerings in emerging markets are well-positioned to capitalize on the growing demand for effective, less invasive BPH treatments.

Market Segmentation Analysis:

The Benign Prostatic Hyperplasia (BPH) treatment market is segmented across drugs, surgery, and end-users, each catering to distinct patient needs and treatment options.

By Drugs Segment: The market for BPH drugs is primarily dominated by three categories. Alpha blockers are widely used due to their ability to relax the muscles in the prostate and bladder neck, improving urine flow. 5-alpha reductase inhibitors are another common drug type, which reduce prostate size by blocking the hormone responsible for prostate growth. Combination drugs, which combine both of these treatment approaches, are gaining popularity due to their enhanced efficacy in managing symptoms and slowing disease progression.

By Surgery Segment: Surgical treatments for BPH include Transurethral Resection of the Prostate (TURP), which remains the gold standard for many patients with severe symptoms. The UroLift System is a newer, minimally invasive procedure that has gained traction for its effectiveness and minimal recovery time. Rezūm Water Vapor Therapy offers an innovative approach to shrink prostate tissue using steam. Open prostatectomy and laser surgery also provide options for patients with severe BPH, though these are typically reserved for more complicated cases.

By End-user Segment: The end-user segment is primarily divided into hospitals, clinics, ambulatory surgical centers, and homecare. Hospitals remain the leading venue for both drug prescriptions and surgical interventions, due to their capacity for handling more complex cases. Clinics and ambulatory surgical centers are increasingly adopting minimally invasive techniques, providing patients with quicker recovery times. Homecare is expanding, with patients seeking more flexible, less invasive treatment options at home.

Segmentation:

By Drugs Segment

Alpha Blockers
5-alpha Reductase Inhibitors
Combination Drugs

By Surgery Segment

Transurethral Resection of the Prostate (TURP)
UroLift System
Rezūm Water Vapor Therapy
Open Prostatectomy
Laser Surgery

By End-user Segment

Hospitals
Clinics
Ambulatory Surgical Centers
Homecare

Regional Analysis:

The Benign Prostatic Hyperplasia (BPH) treatment market is experiencing varied growth across different regions, influenced by factors such as demographic trends, healthcare infrastructure, and technological advancements. North America currently holds the largest share of the global BPH treatment market, accounting for over 40% of the total market share. This dominance is driven by the high prevalence of BPH in the aging male population, coupled with advanced healthcare infrastructure and the availability of cutting-edge treatment options. In particular, the United States has witnessed significant growth due to the growing number of BPH cases and a strong emphasis on minimally invasive procedures. Additionally, the presence of leading medical device manufacturers and pharmaceutical companies in North America further bolsters market growth, as innovations in treatment technologies continue to enhance patient outcomes.

Europe follows closely, capturing a significant portion of the BPH treatment market with a share of around 30%. Countries such as Germany, the United Kingdom, and France exhibit high levels of market activity due to well-established healthcare systems and increasing government initiatives aimed at improving healthcare for the elderly population. The European market is also seeing a steady rise in the adoption of minimally invasive treatment procedures like laser therapies and UroLift, which offer a favorable treatment experience for patients. Furthermore, the aging population in Europe is expected to continue driving demand for BPH treatments, ensuring sustained market growth in the region over the coming years.

In the Asia-Pacific region, the BPH treatment market is expected to experience the fastest growth, This rapid growth is largely attributed to the increasing elderly population in countries like Japan, China, and India, where healthcare infrastructure is improving. While the market share for the Asia-Pacific region is currently smaller compared to North America and Europe, the rising awareness about BPH and growing demand for advanced treatment options are expected to significantly contribute to market expansion. The increasing adoption of minimally invasive procedures and greater access to healthcare services are key drivers of this growth.

The Rest of the World (RoW), which includes regions such as Latin America, the Middle East, and Africa, accounts for a smaller share of the BPH treatment market, estimated at around 10%. However, these regions are expected to see gradual growth due to increasing healthcare investments and improvements in medical technologies. While challenges such as limited access to advanced healthcare services and lower awareness of BPH persist, the expanding elderly population and the rising demand for effective treatment options will drive market development in these regions in the long term.

Key Player Analysis:

GlaxoSmithKline plc
Pfizer Inc.
Eli Lilly and Company
Abbott Laboratories
Boston Scientific Corporation
Teleflex Incorporated
Medtronic plc
Olympus Corporation
Lumenis Ltd.
Urologix, LLC

Competitive Analysis:

The Benign Prostatic Hyperplasia (BPH) treatment market is highly competitive, with several key players operating across the pharmaceutical, medical device, and healthcare sectors. Leading companies such as Boston Scientific, Medtronic, and Abbott Laboratories dominate the market by offering a wide range of BPH treatment solutions, including minimally invasive devices, surgical treatments, and pharmaceutical therapies. Boston Scientific, for example, is a prominent player with its UroLift system, which has gained widespread adoption due to its effectiveness and minimal recovery time. Additionally, pharmaceutical companies like Eli Lilly and Pfizer contribute significantly to the market by providing medications such as alpha-blockers and 5-alpha-reductase inhibitors, which help manage BPH symptoms. The market is also witnessing increasing competition from emerging players who focus on innovative treatment options, such as laser therapies and novel drug formulations, aimed at improving patient outcomes. As the market continues to evolve, companies must prioritize innovation, patient-centric solutions, and regulatory compliance to maintain a competitive edge.

Recent Developments:

In January 2025, Pfizer Inc. partnered with the American Urological Association Education and Research, Inc. (AUAER) to launch a $1.5 million Request for Proposals (RFP) aimed at advancing care for patients with advanced prostate cancer, which is closely related to BPH management. This collaboration focuses on funding innovative quality improvement projects to optimize treatment and reduce disparities in advanced prostate cancer care.
In July 2023, GlaxoSmithKline PLC entered into a significant partnership with Recordati to commercialize Avodart (dutasteride) and Combodart/Duodart (dutasteride/tamsulosin) across 21 countries, primarily in Europe. This agreement excludes countries where GSK already has existing distribution arrangements, thereby expanding the reach of these key benign prostatic hyperplasia (BPH) treatments to new markets and strengthening GSK’s presence in the BPH sector.

Market Concentration & Characteristics:

The Benign Prostatic Hyperplasia (BPH) treatment market exhibits moderate concentration, with a few key players commanding a significant share due to their established presence, extensive product portfolios, and strong brand recognition. Leading companies such as Boston Scientific, Medtronic, and Abbott Laboratories dominate the market by offering advanced medical devices and pharmaceutical therapies. These companies benefit from economies of scale, robust research and development (R&D) capabilities, and established distribution networks, ensuring their products’ availability and accessibility across various regions. Despite the dominance of large players, the market also presents opportunities for smaller companies and emerging players, particularly those focusing on innovative, minimally invasive treatments and novel drug formulations. The market is characterized by continuous technological advancements, patient-centric solutions, and evolving regulatory landscapes. As a result, competition is expected to intensify as companies strive to introduce new, effective treatments that offer improved patient outcomes and address unmet needs in BPH care.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Report Coverage:

The research report offers an in-depth analysis based on Drugs, Surgery and End-user. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook:

The BPH treatment market is expected to witness steady growth due to the increasing aging male population globally.
Advancements in minimally invasive procedures, such as UroLift and laser therapies, will drive greater adoption among patients seeking faster recovery.
Technological innovations in medical devices and drug formulations will enhance treatment precision and improve patient outcomes.
Rising awareness of BPH symptoms and available treatments will increase early diagnoses and intervention rates.
Expansion of healthcare infrastructure in emerging markets will facilitate broader access to BPH treatments.
The growing preference for outpatient treatments will lead to a shift in market dynamics toward more cost-effective, non-surgical options.
Increasing collaborations between pharmaceutical companies and medical device manufacturers will foster the development of comprehensive treatment solutions.
Regulatory approvals for new drugs and devices will create new opportunities for market players to expand their offerings.
The demand for personalized medicine and targeted therapies will lead to more individualized treatment approaches for BPH patients.
Competitive pressure will drive innovation, as companies seek to differentiate themselves through improved safety profiles and superior patient satisfaction.

CHAPTER NO. 1 : INTRODUCTION 28
1.1.1. Report Description 28
Purpose of the Report 28
USP & Key Offerings 28
1.1.2. Key Benefits for Stakeholders 28
1.1.3. Target Audience 29
1.1.4. Report Scope 29
1.1.5. Regional Scope 30
CHAPTER NO. 2 : EXECUTIVE SUMMARY 31
2.1. Benign Prostatic Hyperplasia Treatment Market Snapshot 31
2.1.1. Global Benign Prostatic Hyperplasia Treatment Market, 2018 – 2032 (USD Million) 32
CHAPTER NO. 3 : GEOPOLITICAL CRISIS IMPACT ANALYSIS 33
3.1. Russia-Ukraine and Israel-Palestine War Impacts 33
CHAPTER NO. 4 : BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET – INDUSTRY ANALYSIS 34
4.1. Introduction 34
4.2. Market Drivers 35
4.2.1. Increasing prevalence of BPH among the aging male population 35
4.2.2. Advancements in minimally invasive treatment options 36
4.3. Market Restraints 37
4.3.1. High cost of advanced BPH treatments 37
4.4. Market Opportunities 38
4.4.1. Rising awareness about BPH treatments in developing regions 38
4.5. Porter’s Five Forces Analysis 39
4.6. Value Chain Analysis 40
4.7. Buying Criteria 41
CHAPTER NO. 5 : IMPORT EXPORT ANALYSIS 42
5.1. Import Analysis by Region 42
5.1.1. Global Benign Prostatic Hyperplasia Treatment Market Import Volume/Revenue, By Region, 2018 – 2023 42
5.2. Export Analysis by Region 43
5.2.1. Global Benign Prostatic Hyperplasia Treatment Market Export Volume/Revenue, By Region, 2018 – 2023 43
CHAPTER NO. 6 : DEMAND SUPPLY ANALYSIS 44
6.1. Demand Analysis by Region 44
6.1.1. Global Benign Prostatic Hyperplasia Treatment Market Demand Volume/Revenue, By Region, 2018 – 2023 44
6.2. Supply Analysis by Region 45
6.2.1. Global Benign Prostatic Hyperplasia Treatment Market Supply Volume/Revenue, By Region, 2018 – 2023 45
CHAPTER NO. 7 : PRODUCTION ANALYSIS 46
7.1. Production Analysis by Region 46
7.1.1. Global Benign Prostatic Hyperplasia Treatment Market Production Volume/Revenue, By Region, 2018 – 2023 46
CHAPTER NO. 8 : PRICE ANALYSIS 47
8.1. Price Analysis by Region 47
8.1.1. Global Benign Prostatic Hyperplasia Treatment Market Price, By Region, 2018 – 2023 47
8.1.2. Global Drugs Market Price, By Region, 2018 – 2023 47
8.2. Price Analysis by Drugs 48
8.2.1. Global Benign Prostatic Hyperplasia Treatment Market Price, By Drugs, 2018 – 2023 48
8.2.2. Global Drugs Market Price, By Drugs, 2018 – 2023 48
CHAPTER NO. 9 : RAW MATERIALS ANALYSIS 49
9.1. Key Raw Materials and Suppliers 49
9.2. Key Raw Materials Price Trend 49
CHAPTER NO. 10 : MANUFACTURING COST ANALYSIS 50
10.1. Manufacturing Cost Analysis 50
10.2. Manufacturing Process 50
CHAPTER NO. 11 : ANALYSIS COMPETITIVE LANDSCAPE 51
11.1. Company Market Share Analysis – 2023 51
11.1.1. Global Benign Prostatic Hyperplasia Treatment Market: Company Market Share, by Volume, 2023 51
11.1.2. Global Benign Prostatic Hyperplasia Treatment Market: Company Market Share, by Revenue, 2023 52
11.1.3. Global Benign Prostatic Hyperplasia Treatment Market: Top 6 Company Market Share, by Revenue, 2023 52
11.1.4. Global Benign Prostatic Hyperplasia Treatment Market: Top 3 Company Market Share, by Revenue, 2023 53
11.2. Global Benign Prostatic Hyperplasia Treatment Market Company Volume Market Share, 2023 54
11.3. Global Benign Prostatic Hyperplasia Treatment Market Company Revenue Market Share, 2023 55
11.4. Company Assessment Metrics, 2023 55
11.4.1. Stars 55
11.4.2. Emerging Leaders 55
11.4.3. Pervasive Players 55
11.4.4. Participants 55
11.5. Start-ups /SMEs Assessment Metrics, 2023 55
11.5.1. Progressive Companies 56
11.5.2. Responsive Companies 56
11.5.3. Dynamic Companies 56
11.5.4. Starting Blocks 56
11.6. Strategic Developments 57
11.6.1. Acquisitions & Mergers 57
New Product Launch 57
Regional Expansion 57
11.7. Key Players Product Matrix 58
CHAPTER NO. 12 : PESTEL & ADJACENT MARKET ANALYSIS 59
12.1. PESTEL 59
12.1.1. Political Factors 59
12.1.2. Economic Factors 59
12.1.3. Social Factors 59
12.1.4. Technological Factors 59
12.1.5. Environmental Factors 59
12.1.6. Legal Factors 59
12.2. Adjacent Market Analysis 59
CHAPTER NO. 13 : BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET – BY DRUGS SEGMENT ANALYSIS 60
13.1. Benign Prostatic Hyperplasia Treatment Market Overview, by Drugs Segment 60
13.1.1. Benign Prostatic Hyperplasia Treatment Market Revenue Share, By Drugs, 2023 & 2032 61
13.1.2. Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, By Drugs 62
13.1.3. Incremental Revenue Growth Opportunity, by Drugs, 2024 – 2032 62
13.1.4. Benign Prostatic Hyperplasia Treatment Market Revenue, By Drugs, 2018, 2023, 2027 & 2032 63
13.2. Alpha Blockers 64
13.2.1. Global Alpha Blockers Benign Prostatic Hyperplasia Treatment Market Revenue, By Region, 2018 – 2023 (USD Million) 65
13.2.2. Global Alpha Blockers Benign Prostatic Hyperplasia Treatment Market Revenue, By Region, 2024 – 2032 (USD Million) 65
13.3. 5-alpha Reductase Inhibitors 66
13.3.1. Global 5-alpha Reductase Inhibitors Benign Prostatic Hyperplasia Treatment Market Revenue, By Region, 2018 – 2023 (USD Million) 67
13.3.2. Global 5-alpha Reductase Inhibitors Benign Prostatic Hyperplasia Treatment Market Revenue, By Region, 2024 – 2032 (USD Million) 67
13.4. Combination Drugs 68
13.4.1. Global Combination Drugs Benign Prostatic Hyperplasia Treatment Market Revenue, By Region, 2018 – 2023 (USD Million) 69
13.4.2. Global Combination Drugs Benign Prostatic Hyperplasia Treatment Market Revenue, By Region, 2024 – 2032 (USD Million) 69
CHAPTER NO. 14 : BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET – BY SURGERY SEGMENT ANALYSIS 70
14.1. Benign Prostatic Hyperplasia Treatment Market Overview, by Surgery Segment 70
14.1.1. Benign Prostatic Hyperplasia Treatment Market Revenue Share, By Surgery, 2023 & 2032 71
14.1.2. Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, By Surgery 72
14.1.3. Incremental Revenue Growth Opportunity, by Surgery, 2024 – 2032 72
14.1.4. Benign Prostatic Hyperplasia Treatment Market Revenue, By Surgery, 2018, 2023, 2027 & 2032 73
14.2. Transurethral Resection of the Prostate (TURP) 74
14.2.1. Global Transurethral Resection of the Prostate (TURP) Benign Prostatic Hyperplasia Treatment Market Revenue, By Region, 2018 – 2023 (USD Million) 75
14.2.2. Global Transurethral Resection of the Prostate (TURP) Benign Prostatic Hyperplasia Treatment Market Revenue, By Region, 2024 – 2032 (USD Million) 75
14.3. UroLift System 76
14.3.1. Global UroLift System Benign Prostatic Hyperplasia Treatment Market Revenue, By Region, 2018 – 2023 (USD Million) 77
14.3.2. Global UroLift System Benign Prostatic Hyperplasia Treatment Market Revenue, By Region, 2024 – 2032 (USD Million) 77
14.4. Rezūm Water Vapor Therapy 78
14.4.1. Global Rezūm Water Vapor Therapy Benign Prostatic Hyperplasia Treatment Market Revenue, By Region, 2018 – 2023 (USD Million) 79
14.4.2. Global Rezūm Water Vapor Therapy Benign Prostatic Hyperplasia Treatment Market Revenue, By Region, 2024 – 2032 (USD Million) 79
14.5. Open Prostatectomy 80
14.5.1. Global Open Prostatectomy Benign Prostatic Hyperplasia Treatment Market Revenue, By Region, 2018 – 2023 (USD Million) 81
14.5.2. Global Open Prostatectomy Benign Prostatic Hyperplasia Treatment Market Revenue, By Region, 2024 – 2032 (USD Million) 81
14.6. Laser Surgery 82
14.6.1. Global Laser Surgery Benign Prostatic Hyperplasia Treatment Market Revenue, By Region, 2018 – 2023 (USD Million) 83
14.6.2. Global Laser Surgery Benign Prostatic Hyperplasia Treatment Market Revenue, By Region, 2024 – 2032 (USD Million) 83
CHAPTER NO. 15 : BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET – BY END-USER SEGMENT ANALYSIS 84
15.1. Benign Prostatic Hyperplasia Treatment Market Overview, by End-user Segment 84
15.1.1. Benign Prostatic Hyperplasia Treatment Market Revenue Share, By End-user, 2023 & 2032 85
15.1.2. Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, By End-user 86
15.1.3. Incremental Revenue Growth Opportunity, by End-user, 2024 – 2032 86
15.1.4. Benign Prostatic Hyperplasia Treatment Market Revenue, By End-user, 2018, 2023, 2027 & 2032 87
15.2. Hospitals 88
15.2.1. Global Hospitals Benign Prostatic Hyperplasia Treatment Market Revenue, By Region, 2018 – 2023 (USD Million) 89
15.2.2. Global Hospitals Benign Prostatic Hyperplasia Treatment Market Revenue, By Region, 2024 – 2032 (USD Million) 89
15.3. Clinics 90
15.3.1. Global Clinics Benign Prostatic Hyperplasia Treatment Market Revenue, By Region, 2018 – 2023 (USD Million) 91
15.3.2. Global Clinics Benign Prostatic Hyperplasia Treatment Market Revenue, By Region, 2024 – 2032 (USD Million) 91
15.4. Ambulatory Surgical Centers 92
15.4.1. Global Ambulatory Surgical Centers Benign Prostatic Hyperplasia Treatment Market Revenue, By Region, 2018 – 2023 (USD Million) 93
15.4.2. Global Ambulatory Surgical Centers Benign Prostatic Hyperplasia Treatment Market Revenue, By Region, 2024 – 2032 (USD Million) 93
15.5. Homecare 94
15.5.1. Global Homecare Benign Prostatic Hyperplasia Treatment Market Revenue, By Region, 2018 – 2023 (USD Million) 95
15.5.2. Global Homecare Benign Prostatic Hyperplasia Treatment Market Revenue, By Region, 2024 – 2032 (USD Million) 95
CHAPTER NO. 16 : BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET – REGIONAL ANALYSIS 96
16.1. Benign Prostatic Hyperplasia Treatment Market Overview, by Regional Segments 96
16.2. Region 97
16.2.1. Global Benign Prostatic Hyperplasia Treatment Market Revenue Share, By Region, 2023 & 2032 97
16.2.2. Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, By Region 98
16.2.3. Incremental Revenue Growth Opportunity, by Region, 2024 – 2032 98
16.2.4. Benign Prostatic Hyperplasia Treatment Market Revenue, By Region, 2018, 2023, 2027 & 2032 99
16.2.5. Global Benign Prostatic Hyperplasia Treatment Market Revenue, By Region, 2018 – 2023 (USD Million) 100
16.2.6. Global Benign Prostatic Hyperplasia Treatment Market Revenue, By Region, 2024 – 2032 (USD Million) 100
16.3. Drugs 101
16.3.1. Global Benign Prostatic Hyperplasia Treatment Market Revenue, By Drugs, 2018 – 2023 (USD Million) 101
16.4. Global Benign Prostatic Hyperplasia Treatment Market Revenue, By Drugs, 2024 – 2032 (USD Million) 101
16.5. Surgery 102
16.5.1. Global Benign Prostatic Hyperplasia Treatment Market Revenue, By Surgery, 2018 – 2023 (USD Million) 102
16.5.2. Global Benign Prostatic Hyperplasia Treatment Market Revenue, By Surgery, 2024 – 2032 (USD Million) 102
16.6. End-user 103
16.6.1. Global Benign Prostatic Hyperplasia Treatment Market Revenue, By End-user, 2018 – 2023 (USD Million) 103
16.6.2. Global Benign Prostatic Hyperplasia Treatment Market Revenue, By End-user, 2024 – 2032 (USD Million) 103
CHAPTER NO. 17 : BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET – NORTH AMERICA 104
17.1. North America 104
17.1.1. Key Highlights 104
17.1.2. North America Benign Prostatic Hyperplasia Treatment Market Revenue, By Country, 2018 – 2023 (USD Million) 105
17.1.3. North America Benign Prostatic Hyperplasia Treatment Market Revenue, By Drugs, 2018 – 2023 (USD Million) 106
17.1.4. North America Benign Prostatic Hyperplasia Treatment Market Revenue, By Surgery, 2018 – 2023 (USD Million) 107
17.1.5. North America Benign Prostatic Hyperplasia Treatment Market Revenue, By End-user, 2018 – 2023 (USD Million) 108
17.2. U.S. 109
17.3. Canada 109
17.4. Mexico 109
CHAPTER NO. 18 : BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET – EUROPE 110
18.1. Europe 110
18.1.1. Key Highlights 110
18.1.2. Europe Benign Prostatic Hyperplasia Treatment Market Revenue, By Country, 2018 – 2023 (USD Million) 111
18.1.3. Europe Benign Prostatic Hyperplasia Treatment Market Revenue, By Drugs, 2018 – 2023 (USD Million) 112
18.1.4. Europe Benign Prostatic Hyperplasia Treatment Market Revenue, By Surgery, 2018 – 2023 (USD Million) 113
18.1.5. Europe Benign Prostatic Hyperplasia Treatment Market Revenue, By End-user, 2018 – 2023 (USD Million) 114
18.2. UK 115
18.3. France 115
18.4. Germany 115
18.5. Italy 115
18.6. Spain 115
18.7. Russia 115
18.8. Belgium 115
18.9. Netherland 115
18.10. Austria 115
18.11. Sweden 115
18.12. Poland 115
18.13. Denmark 115
18.14. Switzerland 115
18.15. Rest of Europe 115
CHAPTER NO. 19 : BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET – ASIA PACIFIC 116
19.1. Asia Pacific 116
19.1.1. Key Highlights 116
19.1.2. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Revenue, By Country, 2018 – 2023 (USD Million) 117
19.1.3. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Revenue, By Drugs, 2018 – 2023 (USD Million) 118
19.1.4. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Revenue, By Surgery, 2018 – 2023 (USD Million) 119
19.1.5. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Revenue, By End-user, 2018 – 2023 (USD Million) 120
19.2. China 121
19.3. Japan 121
19.4. South Korea 121
19.5. India 121
19.6. Australia 121
19.7. Thailand 121
19.8. Indonesia 121
19.9. Vietnam 121
19.10. Malaysia 121
19.11. Philippines 121
19.12. Taiwan 121
19.13. Rest of Asia Pacific 121
CHAPTER NO. 20 : BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET – LATIN AMERICA 122
20.1. Latin America 122
20.1.1. Key Highlights 122
20.1.2. Latin America Benign Prostatic Hyperplasia Treatment Market Revenue, By Country, 2018 – 2023 (USD Million) 123
20.1.3. Latin America Benign Prostatic Hyperplasia Treatment Market Revenue, By Drugs, 2018 – 2023 (USD Million) 124
20.1.4. Latin America Benign Prostatic Hyperplasia Treatment Market Revenue, By Surgery, 2018 – 2023 (USD Million) 125
20.1.5. Latin America Benign Prostatic Hyperplasia Treatment Market Revenue, By End-user, 2018 – 2023 (USD Million) 126
20.2. Brazil 127
20.3. Argentina 127
20.4. Peru 127
20.5. Chile 127
20.6. Colombia 127
20.7. Rest of Latin America 127
CHAPTER NO. 21 : BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET – MIDDLE EAST 128
21.1. Middle East 128
21.1.1. Key Highlights 128
21.1.2. Middle East Benign Prostatic Hyperplasia Treatment Market Revenue, By Country, 2018 – 2023 (USD Million) 129
21.1.3. Middle East Benign Prostatic Hyperplasia Treatment Market Revenue, By Drugs, 2018 – 2023 (USD Million) 130
21.1.4. Middle East Benign Prostatic Hyperplasia Treatment Market Revenue, By Surgery, 2018 – 2023 (USD Million) 131
21.1.5. Middle East Benign Prostatic Hyperplasia Treatment Market Revenue, By End-user, 2018 – 2023 (USD Million) 132
21.2. UAE 133
21.3. KSA 133
21.4. Israel 133
21.5. Turkey 133
21.6. Iran 133
21.7. Rest of Middle East 133
CHAPTER NO. 22 : BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET – AFRICA 134
22.1. Africa 134
22.1.1. Key Highlights 134
22.1.2. Africa Benign Prostatic Hyperplasia Treatment Market Revenue, By Country, 2018 – 2023 (USD Million) 135
22.1.3. Africa Benign Prostatic Hyperplasia Treatment Market Revenue, By Drugs, 2018 – 2023 (USD Million) 136
22.1.4. Africa Benign Prostatic Hyperplasia Treatment Market Revenue, By Surgery, 2018 – 2023 (USD Million) 137
22.1.5. Africa Benign Prostatic Hyperplasia Treatment Market Revenue, By End-user, 2018 – 2023 (USD Million) 138
22.2. Egypt 139
22.3. Nigeria 139
22.4. Algeria 139
22.5. Morocco 139
22.6. Rest of Africa 139
CHAPTER NO. 23 : COMPANY PROFILES 140
23.1. GlaxoSmithKline plc 140
23.1.1. Company Overview 140
23.1.2. Product Portfolio 140
23.1.3. Swot Analysis 140
23.1.4. Business Strategy 141
23.1.5. Financial Overview 141
23.2. Pfizer Inc. 142
23.3. Eli Lilly and Company 142
23.4. Abbott Laboratories 142
23.5. Boston Scientific Corporation 142
23.6. Teleflex Incorporated 142
23.7. Medtronic plc 142
23.8. Olympus Corporation 142
23.9. Lumenis Ltd. 142
23.10. Urologix, LLC 142

List of Figures
FIG NO. 1. Global Benign Prostatic Hyperplasia Treatment Market Revenue, 2018 – 2032 (USD Million) 36
FIG NO. 2. Porter’s Five Forces Analysis for Global Benign Prostatic Hyperplasia Treatment Market 43
FIG NO. 3. Value Chain Analysis for Global Benign Prostatic Hyperplasia Treatment Market 44
FIG NO. 4. Global Benign Prostatic Hyperplasia Treatment Market Import Volume/Revenue, By Region, 2018 – 2023 46
FIG NO. 5. Global Benign Prostatic Hyperplasia Treatment Market Export Volume/Revenue, By Region, 2018 – 2023 47
FIG NO. 6. Global Benign Prostatic Hyperplasia Treatment Market Demand Volume/Revenue, By Region, 2018 – 2023 48
FIG NO. 7. Global Benign Prostatic Hyperplasia Treatment Market Supply Volume/Revenue, By Region, 2018 – 2023 49
FIG NO. 8. Global Benign Prostatic Hyperplasia Treatment Market Production Volume/Revenue, By Region, 2018 – 2023 50
FIG NO. 9. Global Benign Prostatic Hyperplasia Treatment Market Price, By Region, 2018 – 2023 51
FIG NO. 10. Global Benign Prostatic Hyperplasia Treatment Market Price, By Drugs, 2018 – 2023 52
FIG NO. 11. Raw Materials Price Trend Analysis, 2018 – 2023 53
FIG NO. 12. Manufacturing Cost Analysis 54
FIG NO. 13. Manufacturing Process 54
FIG NO. 14. Company Share Analysis, 2023 55
FIG NO. 15. Company Share Analysis, 2023 56
FIG NO. 16. Company Share Analysis, 2023 56
FIG NO. 17. Company Share Analysis, 2023 57
FIG NO. 18. Benign Prostatic Hyperplasia Treatment Market – Company Volume Market Share, 2023 58
FIG NO. 19. Benign Prostatic Hyperplasia Treatment Market – Company Revenue Market Share, 2023 59
FIG NO. 20. Benign Prostatic Hyperplasia Treatment Market Revenue Share, By Drugs, 2023 & 2032 65
FIG NO. 21. Market Attractiveness Analysis, By Drugs 66
FIG NO. 22. Incremental Revenue Growth Opportunity by Drugs, 2024 – 2032 66
FIG NO. 23. Benign Prostatic Hyperplasia Treatment Market Revenue, By Drugs, 2018, 2023, 2027 & 2032 67
FIG NO. 24. Global Benign Prostatic Hyperplasia Treatment Market for Alpha Blockers, Revenue (USD Million) 2018 – 2032 68
FIG NO. 25. Global Benign Prostatic Hyperplasia Treatment Market for 5-alpha Reductase Inhibitors, Revenue (USD Million) 2018 – 2032 70
FIG NO. 26. Global Benign Prostatic Hyperplasia Treatment Market for Combination Drugs, Revenue (USD Million) 2018 – 2032 72
FIG NO. 27. Benign Prostatic Hyperplasia Treatment Market Revenue Share, By Surgery, 2023 & 2032 75
FIG NO. 28. Market Attractiveness Analysis, By Surgery 76
FIG NO. 29. Incremental Revenue Growth Opportunity by Surgery, 2024 – 2032 76
FIG NO. 30. Benign Prostatic Hyperplasia Treatment Market Revenue, By Surgery, 2018, 2023, 2027 & 2032 77
FIG NO. 31. Global Benign Prostatic Hyperplasia Treatment Market for Transurethral Resection of the Prostate (TURP), Revenue (USD Million) 2018 – 2032 78
FIG NO. 32. Global Benign Prostatic Hyperplasia Treatment Market for UroLift System, Revenue (USD Million) 2018 – 2032 80
FIG NO. 33. Global Benign Prostatic Hyperplasia Treatment Market for Rezūm Water Vapor Therapy, Revenue (USD Million) 2018 – 2032 82
FIG NO. 34. Global Benign Prostatic Hyperplasia Treatment Market for Open Prostatectomy, Revenue (USD Million) 2018 – 2032 84
FIG NO. 35. Global Benign Prostatic Hyperplasia Treatment Market for Laser Surgery, Revenue (USD Million) 2018 – 2032 86
FIG NO. 36. Benign Prostatic Hyperplasia Treatment Market Revenue Share, By End-user, 2023 & 2032 89
FIG NO. 37. Market Attractiveness Analysis, By End-user 90
FIG NO. 38. Incremental Revenue Growth Opportunity by End-user, 2024 – 2032 90
FIG NO. 39. Benign Prostatic Hyperplasia Treatment Market Revenue, By End-user, 2018, 2023, 2027 & 2032 91
FIG NO. 40. Global Benign Prostatic Hyperplasia Treatment Market for Hospitals, Revenue (USD Million) 2018 – 2032 92
FIG NO. 41. Global Benign Prostatic Hyperplasia Treatment Market for Clinics, Revenue (USD Million) 2018 – 2032 94
FIG NO. 42. Global Benign Prostatic Hyperplasia Treatment Market for Ambulatory Surgical Centers, Revenue (USD Million) 2018 – 2032 96
FIG NO. 43. Global Benign Prostatic Hyperplasia Treatment Market for Homecare, Revenue (USD Million) 2018 – 2032 98
FIG NO. 44. Global Benign Prostatic Hyperplasia Treatment Market Revenue Share, By Region, 2023 & 2032 101
FIG NO. 45. Market Attractiveness Analysis, By Region 102
FIG NO. 46. Incremental Revenue Growth Opportunity by Region, 2024 – 2032 102
FIG NO. 47. Benign Prostatic Hyperplasia Treatment Market Revenue, By Region, 2018, 2023, 2027 & 2032 103
FIG NO. 48. North America Benign Prostatic Hyperplasia Treatment Market Revenue, 2018 – 2032 (USD Million) 108
FIG NO. 49. Europe Benign Prostatic Hyperplasia Treatment Market Revenue, 2018 – 2032 (USD Million) 114
FIG NO. 50. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Revenue, 2018 – 2032 (USD Million) 120
FIG NO. 51. Latin America Benign Prostatic Hyperplasia Treatment Market Revenue, 2018 – 2032 (USD Million) 126
FIG NO. 52. Middle East Benign Prostatic Hyperplasia Treatment Market Revenue, 2018 – 2032 (USD Million) 132
FIG NO. 53. Africa Benign Prostatic Hyperplasia Treatment Market Revenue, 2018 – 2032 (USD Million) 138

List of Tables
TABLE NO. 1. : Global Benign Prostatic Hyperplasia Treatment Market: Snapshot 35
TABLE NO. 2. : Drivers for the Benign Prostatic Hyperplasia Treatment Market: Impact Analysis 39
TABLE NO. 3. : Restraints for the Benign Prostatic Hyperplasia Treatment Market: Impact Analysis 41
TABLE NO. 4. : Global Benign Prostatic Hyperplasia Treatment Market Revenue, By Region, 2018 – 2023 51
TABLE NO. 5. : Global Benign Prostatic Hyperplasia Treatment Market Revenue, By Drugs, 2018 – 2023 52
TABLE NO. 6. : Key Raw Materials & Suppliers 53
TABLE NO. 7. : Global Alpha Blockers Benign Prostatic Hyperplasia Treatment Market Revenue, By Region, 2018 – 2023 (USD Million) 69
TABLE NO. 8. : Global Alpha Blockers Benign Prostatic Hyperplasia Treatment Market Revenue, By Region, 2024 – 2032 (USD Million) 69
TABLE NO. 9. : Global 5-alpha Reductase Inhibitors Benign Prostatic Hyperplasia Treatment Market Revenue, By Region, 2018 – 2023 (USD Million) 71
TABLE NO. 10. : Global 5-alpha Reductase Inhibitors Benign Prostatic Hyperplasia Treatment Market Revenue, By Region, 2024 – 2032 (USD Million) 71
TABLE NO. 11. : Global Combination Drugs Benign Prostatic Hyperplasia Treatment Market Revenue, By Region, 2018 – 2023 (USD Million) 73
TABLE NO. 12. : Global Combination Drugs Benign Prostatic Hyperplasia Treatment Market Revenue, By Region, 2024 – 2032 (USD Million) 73
TABLE NO. 13. : Global Transurethral Resection of the Prostate (TURP) Benign Prostatic Hyperplasia Treatment Market Revenue, By Region, 2018 – 2023 (USD Million) 79
TABLE NO. 14. : Global Transurethral Resection of the Prostate (TURP) Benign Prostatic Hyperplasia Treatment Market Revenue, By Region, 2024 – 2032 (USD Million) 79
TABLE NO. 15. : Global UroLift System Benign Prostatic Hyperplasia Treatment Market Revenue, By Region, 2018 – 2023 (USD Million) 81
TABLE NO. 16. : Global UroLift System Benign Prostatic Hyperplasia Treatment Market Revenue, By Region, 2024 – 2032 (USD Million) 81
TABLE NO. 17. : Global Rezūm Water Vapor Therapy Benign Prostatic Hyperplasia Treatment Market Revenue, By Region, 2018 – 2023 (USD Million) 83
TABLE NO. 18. : Global Rezūm Water Vapor Therapy Benign Prostatic Hyperplasia Treatment Market Revenue, By Region, 2024 – 2032 (USD Million) 83
TABLE NO. 19. : Global Open Prostatectomy Benign Prostatic Hyperplasia Treatment Market Revenue, By Region, 2018 – 2023 (USD Million) 85
TABLE NO. 20. : Global Open Prostatectomy Benign Prostatic Hyperplasia Treatment Market Revenue, By Region, 2024 – 2032 (USD Million) 85
TABLE NO. 21. : Global Laser Surgery Benign Prostatic Hyperplasia Treatment Market Revenue, By Region, 2018 – 2023 (USD Million) 87
TABLE NO. 22. : Global Laser Surgery Benign Prostatic Hyperplasia Treatment Market Revenue, By Region, 2024 – 2032 (USD Million) 87
TABLE NO. 23. : Global Hospitals Benign Prostatic Hyperplasia Treatment Market Revenue, By Region, 2018 – 2023 (USD Million) 93
TABLE NO. 24. : Global Hospitals Benign Prostatic Hyperplasia Treatment Market Revenue, By Region, 2024 – 2032 (USD Million) 93
TABLE NO. 25. : Global Clinics Benign Prostatic Hyperplasia Treatment Market Revenue, By Region, 2018 – 2023 (USD Million) 95
TABLE NO. 26. : Global Clinics Benign Prostatic Hyperplasia Treatment Market Revenue, By Region, 2024 – 2032 (USD Million) 95
TABLE NO. 27. : Global Ambulatory Surgical Centers Benign Prostatic Hyperplasia Treatment Market Revenue, By Region, 2018 – 2023 (USD Million) 97
TABLE NO. 28. : Global Ambulatory Surgical Centers Benign Prostatic Hyperplasia Treatment Market Revenue, By Region, 2024 – 2032 (USD Million) 97
TABLE NO. 29. : Global Homecare Benign Prostatic Hyperplasia Treatment Market Revenue, By Region, 2018 – 2023 (USD Million) 99
TABLE NO. 30. : Global Homecare Benign Prostatic Hyperplasia Treatment Market Revenue, By Region, 2024 – 2032 (USD Million) 99
TABLE NO. 31. : Global Benign Prostatic Hyperplasia Treatment Market Revenue, By Region, 2018 – 2023 (USD Million) 104
TABLE NO. 32. : Global Benign Prostatic Hyperplasia Treatment Market Revenue, By Region, 2024 – 2032 (USD Million) 104
TABLE NO. 33. : Global Benign Prostatic Hyperplasia Treatment Market Revenue, By Drugs, 2018 – 2023 (USD Million) 105
TABLE NO. 34. : Global Benign Prostatic Hyperplasia Treatment Market Revenue, By Drugs, 2024 – 2032 (USD Million) 105
TABLE NO. 35. : Global Benign Prostatic Hyperplasia Treatment Market Revenue, By Surgery, 2018 – 2023 (USD Million) 106
TABLE NO. 36. : Global Benign Prostatic Hyperplasia Treatment Market Revenue, By Surgery, 2024 – 2032 (USD Million) 106
TABLE NO. 37. : Global Benign Prostatic Hyperplasia Treatment Market Revenue, By End-user, 2018 – 2023 (USD Million) 107
TABLE NO. 38. : Global Benign Prostatic Hyperplasia Treatment Market Revenue, By End-user, 2024 – 2032 (USD Million) 107
TABLE NO. 39. : North America Benign Prostatic Hyperplasia Treatment Market Revenue, By Country, 2018 – 2023 (USD Million) 109
TABLE NO. 40. : North America Benign Prostatic Hyperplasia Treatment Market Revenue, By Country, 2024 – 2032 (USD Million) 109
TABLE NO. 41. : North America Benign Prostatic Hyperplasia Treatment Market Revenue, By Drugs, 2018 – 2023 (USD Million) 110
TABLE NO. 42. : North America Benign Prostatic Hyperplasia Treatment Market Revenue, By Drugs, 2024 – 2032 (USD Million) 110
TABLE NO. 43. : North America Benign Prostatic Hyperplasia Treatment Market Revenue, By Surgery, 2018 – 2023 (USD Million) 111
TABLE NO. 44. : North America Benign Prostatic Hyperplasia Treatment Market Revenue, By Surgery, 2024 – 2032 (USD Million) 111
TABLE NO. 45. : North America Benign Prostatic Hyperplasia Treatment Market Revenue, By End-user, 2018 – 2023 (USD Million) 112
TABLE NO. 46. : North America Benign Prostatic Hyperplasia Treatment Market Revenue, By End-user, 2024 – 2032 (USD Million) 112
TABLE NO. 47. : Europe Benign Prostatic Hyperplasia Treatment Market Revenue, By Country, 2018 – 2023 (USD Million) 115
TABLE NO. 48. : Europe Benign Prostatic Hyperplasia Treatment Market Revenue, By Country, 2024 – 2032 (USD Million) 115
TABLE NO. 49. : Europe Benign Prostatic Hyperplasia Treatment Market Revenue, By Drugs, 2018 – 2023 (USD Million) 116
TABLE NO. 50. : Europe Benign Prostatic Hyperplasia Treatment Market Revenue, By Drugs, 2024 – 2032 (USD Million) 116
TABLE NO. 51. : Europe Benign Prostatic Hyperplasia Treatment Market Revenue, By Surgery, 2018 – 2023 (USD Million) 117
TABLE NO. 52. : Europe Benign Prostatic Hyperplasia Treatment Market Revenue, By Surgery, 2024 – 2032 (USD Million) 117
TABLE NO. 53. : Europe Benign Prostatic Hyperplasia Treatment Market Revenue, By End-user, 2018 – 2023 (USD Million) 118
TABLE NO. 54. : Europe Benign Prostatic Hyperplasia Treatment Market Revenue, By End-user, 2024 – 2032 (USD Million) 118
TABLE NO. 55. : Asia Pacific Benign Prostatic Hyperplasia Treatment Market Revenue, By Country, 2018 – 2023 (USD Million) 121
TABLE NO. 56. : Asia Pacific Benign Prostatic Hyperplasia Treatment Market Revenue, By Country, 2024 – 2032 (USD Million) 121
TABLE NO. 57. : Asia Pacific Benign Prostatic Hyperplasia Treatment Market Revenue, By Drugs, 2018 – 2023 (USD Million) 122
TABLE NO. 58. : Asia Pacific Benign Prostatic Hyperplasia Treatment Market Revenue, By Drugs, 2024 – 2032 (USD Million) 122
TABLE NO. 59. : Asia Pacific Benign Prostatic Hyperplasia Treatment Market Revenue, By Surgery, 2018 – 2023 (USD Million) 123
TABLE NO. 60. : Asia Pacific Benign Prostatic Hyperplasia Treatment Market Revenue, By Surgery, 2024 – 2032 (USD Million) 123
TABLE NO. 61. : Asia Pacific Benign Prostatic Hyperplasia Treatment Market Revenue, By End-user, 2018 – 2023 (USD Million) 124
TABLE NO. 62. : Asia Pacific Benign Prostatic Hyperplasia Treatment Market Revenue, By End-user, 2024 – 2032 (USD Million) 124
TABLE NO. 63. : Latin America Benign Prostatic Hyperplasia Treatment Market Revenue, By Country, 2018 – 2023 (USD Million) 127
TABLE NO. 64. : Latin America Benign Prostatic Hyperplasia Treatment Market Revenue, By Country, 2024 – 2032 (USD Million) 127
TABLE NO. 65. : Latin America Benign Prostatic Hyperplasia Treatment Market Revenue, By Drugs, 2018 – 2023 (USD Million) 128
TABLE NO. 66. : Latin America Benign Prostatic Hyperplasia Treatment Market Revenue, By Drugs, 2024 – 2032 (USD Million) 128
TABLE NO. 67. : Latin America Benign Prostatic Hyperplasia Treatment Market Revenue, By Surgery, 2018 – 2023 (USD Million) 129
TABLE NO. 68. : Latin America Benign Prostatic Hyperplasia Treatment Market Revenue, By Surgery, 2024 – 2032 (USD Million) 129
TABLE NO. 69. : Latin America Benign Prostatic Hyperplasia Treatment Market Revenue, By End-user, 2018 – 2023 (USD Million) 130
TABLE NO. 70. : Latin America Benign Prostatic Hyperplasia Treatment Market Revenue, By End-user, 2024 – 2032 (USD Million) 130
TABLE NO. 71. : Middle East Benign Prostatic Hyperplasia Treatment Market Revenue, By Country, 2018 – 2023 (USD Million) 133
TABLE NO. 72. : Middle East Benign Prostatic Hyperplasia Treatment Market Revenue, By Country, 2024 – 2032 (USD Million) 133
TABLE NO. 73. : Middle East Benign Prostatic Hyperplasia Treatment Market Revenue, By Drugs, 2018 – 2023 (USD Million) 134
TABLE NO. 74. : Middle East Benign Prostatic Hyperplasia Treatment Market Revenue, By Drugs, 2024 – 2032 (USD Million) 134
TABLE NO. 75. : Middle East Benign Prostatic Hyperplasia Treatment Market Revenue, By Surgery, 2018 – 2023 (USD Million) 135
TABLE NO. 76. : Middle East Benign Prostatic Hyperplasia Treatment Market Revenue, By Surgery, 2024 – 2032 (USD Million) 135
TABLE NO. 77. : Middle East Benign Prostatic Hyperplasia Treatment Market Revenue, By End-user, 2018 – 2023 (USD Million) 136
TABLE NO. 78. : Middle East Benign Prostatic Hyperplasia Treatment Market Revenue, By End-user, 2024 – 2032 (USD Million) 136
TABLE NO. 79. : Africa Benign Prostatic Hyperplasia Treatment Market Revenue, By Country, 2018 – 2023 (USD Million) 139
TABLE NO. 80. : Africa Benign Prostatic Hyperplasia Treatment Market Revenue, By Country, 2024 – 2032 (USD Million) 139
TABLE NO. 81. : Africa Benign Prostatic Hyperplasia Treatment Market Revenue, By Drugs, 2018 – 2023 (USD Million) 140
TABLE NO. 82. : Africa Benign Prostatic Hyperplasia Treatment Market Revenue, By Drugs, 2024 – 2032 (USD Million) 140
TABLE NO. 83. : Africa Benign Prostatic Hyperplasia Treatment Market Revenue, By Surgery, 2018 – 2023 (USD Million) 141
TABLE NO. 84. : Africa Benign Prostatic Hyperplasia Treatment Market Revenue, By Surgery, 2024 – 2032 (USD Million) 141
TABLE NO. 85. : Africa Benign Prostatic Hyperplasia Treatment Market Revenue, By End-user, 2018 – 2023 (USD Million) 142
TABLE NO. 86. : Africa Benign Prostatic Hyperplasia Treatment Market Revenue, By End-user, 2024 – 2032 (USD Million) 142

Frequently Asked Questions:

What is the current size of the Benign Prostatic Hyperplasia Treatment Market?

The Benign Prostatic Hyperplasia (BPH) treatment market was valued at USD 2.12 billion in 2024 and is expected to reach USD 4.29 billion by 2032, growing at a CAGR of 9.2% during the forecast period.

What factors are driving the growth of the Benign Prostatic Hyperplasia Treatment Market?

The growth of the BPH treatment market is driven by the expanding aging male population, increasing adoption of minimally invasive surgical procedures like laser therapies and UroLift systems, and advancements in diagnostic tools that enhance treatment precision and outcomes.

What are the key segments within the Benign Prostatic Hyperplasia Treatment Market?

The key segments within the BPH treatment market include minimally invasive treatments, pharmaceutical therapies, and diagnostic tools. These segments are further categorized based on treatment methods, such as laser therapies, UroLift, and medications like alpha-blockers and 5-alpha-reductase inhibitors.

What are some challenges faced by the Benign Prostatic Hyperplasia Treatment Market?

Key challenges include high treatment costs, particularly for advanced minimally invasive procedures, a lack of awareness in emerging markets, and the potential for treatment-related side effects or complications, which may deter some patients from opting for advanced therapies.

Who are the major players in the Benign Prostatic Hyperplasia Treatment Market?

Major players in the BPH treatment market include Boston Scientific, Medtronic, Abbott Laboratories, and Eli Lilly. These companies lead the market by offering a range of devices, medications, and advanced treatment options for BPH management.

Purchase Options

Single User

$4699

Multi User

$5699

Custom Report

$7699

Let us help you

MIKE, North America

+1 304 308 1216

KEITH PHILLIPS, Europe

+44 7809 866 263

EMAIL US

Request Sample

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –